Brind.

Aurinia's LUPKYNIS received FDA approval on July 31, 2025.

4 reports, 2 independent Updated Jun 29

Gone quiet

Reports: 4
Developments: 2
Repetition: 75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Aurinia's LUPKYNIS received FDA approval on July 31, 2025.

Who's involved

What this event is mainly about

Aurinia (Canada)FDA

How it developed

Newest first. Tap a step to see who reported it.

Aug 28Teva is challenging Aurinia's patents regarding LUPKYNIS, while Aurinia defends against generic applications from Sandoz.Sub-event
Jul 31Aurinia's LUPKYNIS received FDA approval.1 source
- Business Wire

Keep exploring

The entities involved

Aurinia (Canada)
company in Victoria, Canada

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Jun 29insidermonkey.com
Jul 31Business WireAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 ROCKVILLE, Md.& EDMONTON, Alberta, July 31, 2025--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NAS
Jun 30Unknown outlet

1 more outlet ran the same wire story

Jun 29yahoo.com